AEterna Zentaris (USA) (AEZS) announced its most recent quarterly financial results on Wednesday, Mar-15-2017. AEZS said it had a profit of $-0.71 Earnings per Share for the quarter. The results exceeded Wall Street expectations beating the analyst consensus estimate by $0.02. Analysts had a consensus of $-0.73. The company posted revenue of $.30 million in the period, compared to analysts expectations of $.40 million. AEZS’s revenue was up 200.0% compared to the same quarter last year. During the same quarter in the previous year, the company posted $-1.46 EPS.
Based on several research reports , Company shares were Reiterated by Maxim Group on Jan 17, 2017 to “Buy”, Firm has raised the Price Target to $ 10 from a previous price target of $7 .
AEterna Zentaris (USA) opened for trading at $2.9 and hit $3 on the upside on Wednesday, eventually ending the session at $3, with a gain of 3.45% or 0.1 points. The heightened volatility saw the trading volume jump to 81,123 shares. Company has a market cap of $35 M.
Aeterna Zentaris Inc. is a Canada-based specialty biopharmaceutical company engaged in developing treatments in oncology endocrinology and women’s health. The Company has three wholly owned direct and indirect subsidiaries: AEZS GmbH based in Frankfurt Germany Zentaris IVF GmbH a direct wholly owned subsidiary of AEZS Germany based in Frankfurt Germany and Aeterna Zentaris Inc. Its drug development efforts are focused on two compounds zoptarelin doxorubicin and Macrilen which are in clinical development and on two oncology compounds (an Erk inhibitor and Luteinizing Hormone-Releasing Hormone-disorazol Z product candidates) which are in pre-clinical development. Zoptarelin doxorubicin represents a hybrid molecule composed of a synthetic peptide carrier and a chemotherapy agent doxorubicin. Macrilen (macimorelin acetate) is an orally available peptidomimetic ghrelin receptor agonist that stimulates the secretion of growth hormone by binding to the ghrelin receptor.